key: cord-0785536-4yt7krng
authors: Yadav, Kunal; Sindhwani, Puneet; Ekwenna, Obinna; Malhotra, Deepak; Kaw, Dinkar; Ratnam, Shobha; Alam, Zubia; Flick, Sandra; Scott, Tina; Rees, Michael
title: Optimal timing of COVID-19 vaccination in the peri-transplant period: a single institution case series
date: 2022-02-01
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2022.01.021
sha: c34a72feca57edc246badc5ab04d862f43b71fae
doc_id: 785536
cord_uid: 4yt7krng

Outcomes of vaccination against SARS-COV-2 in organ transplant recipients are unclear. Recent studies have investigated outcomes for patients who are several years post-transplant. There hasn't been much data in peri-transplant patients. This is important because patients are highly immunosuppressed during this period due to induction immunosuppression and thus susceptible to infection. We looked at 6 patients who were transplanted at our center after receiving their first dose of mRNA vaccines. We assessed their antibody response after one, two and in a few cases, three doses of the vaccine. Two patients received their third booster dose, one of whom had a detectable antibody level after the third dose. We report that the overall antibody response to vaccination was weaker in transplant patients compared to the general population with a rapid attrition of antibody response over time. There is a need for more studies which follow-up antibody levels in transplant patients over time, especially those in the peri-transplant period to help guide the vaccination plan and frequency for immunosuppressed transplant patients.

this period due to induction immunosuppression and thus susceptible to infection. We looked at 6 patients who were transplanted at our center after receiving their first dose of mRNA vaccines. We assessed their antibody response after one, two and in a few cases, three doses of the vaccine. Two patients received their third booster dose, one of whom had a detectable antibody level after the third dose. We report that the overall antibody response to vaccination was weaker in transplant patients compared to the general population with a rapid attrition of antibody response over time. There is a need for more studies which follow-up antibody levels in transplant patients over time, especially those in the peri-transplant period to help guide the vaccination plan and frequency for immunosuppressed transplant patients.

Vaccination against SARS-COV-2 with mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines has been noted to be highly effective in the general population (1, 2) . However, the outcomes in immunocompromised transplant recipients are unclear from the original studies because these individuals were excluded from those studies. There has been a recent report to assess the immunogenicity of a single dose of the mRNA vaccines in solid organ transplant recipients (3) . The authors reported that only 17% patients had a detectable antibody response after a single dose of the mRNA vaccine. More recently, the same group reported the outcomes after both doses of vaccine.

Antibody was detectable in 54% of the patients after the second dose (4) . Compared to this, the antibody response in dialysis patients has been reported to be better, with 90-96% patients with detectable antibody after both doses of the vaccine, albeit with a much lower antibody titer compared to the general population (5, 6) . The median time since transplant for these patients was 6.2 years. There is still no data about vaccine efficacy in the peri-transplant period.

Many unanswered questions remain when a kidney becomes available for a waitlisted patient: During follow-up, we tested the patients using an enzyme immunoassay (EUROIMMUN SARS-COV-2 ELISA) for detection of IgG antibodies against the spike protein (S1) of SARS-CoV-2, a median of 44.5 days (19-48 days) after vaccination. Per lab protocol, a reference interval index of <0.7 was a negative test, >1.1 index was considered positive and an index of 0.8-1.0 was considered indeterminate.

After the first dose, four patients had negative antibody tests, while two patients had detectable antispike protein IgG antibodies. After the second dose, two patients had detectable antibodies, 3 patients were negative, and one was indeterminate due to low titer of antibodies.

Interestingly, two patients (patients 5 and 6) who had detectable antibodies after the first vaccine dose had undetectable antibodies after the second dose, while two patients who had undetectable antibodies after first dose had detectable antibodies after the second dose. One patient (patient 2) continued to have no detectable antibodies after the second dose and more recently after the third (booster) dose as well. Another patient (patient 3) had indeterminate levels of antibodies (index -0.9) after the second dose but became positive after a third booster dose of the vaccine. None of the patients contracted COVID-19 infection before or after transplant.

While this is a small single center case series, we did find that the antibody response to the first dose in these patients was weak with only 2/6 patients with detectable antibody levels. Both these patients who had a positive antibody response got their test within 30 days of receiving the vaccine. Other patients who had their antibody levels checked more than 30 days after getting their first shot had undetectable antibody level. This is likely attributable to the rapid attrition of antibodies in immunosuppressed transplant patients which is much quicker than in the general population [7, 8] .

We also found in this small series that patients receiving Moderna vaccine had more likelihood of having detectable antibody level after two doses than patients receiving Pfizer-BioNtech vaccine.

Two patients (patient 2 and 3), both without adequate detectable antibody response after the first two vaccine doses, received a third booster dose. While patient 3 was able to mount an antibody response after that, patient 2 continued to have undetectable antibody level even after the booster dose.

Given the results of this study and the data on immunogenicity of vaccines post-tx (3, 4) , and in dialysis patients (5, 6) we recommend fully vaccinating patients prior to activating on the waitlist and placing the waitlisted kidney transplant patients on hold till they receive both doses of the vaccine, as recommended by American Society of Transplantation (9).

In case a patient is transplanted after a single mRNA vaccine dose, we suggest waiting for at least 6 weeks, getting a second dose of the vaccine, followed by a third booster dose [10] and then testing for the presence of anti-spike protein IgG antibodies after that to determine if additional vaccine doses are warranted. A fourth dose of the vaccine is not currently approved by the FDA. It is also uncertain if the patients not responding to the first three doses of the vaccine will respond to a fourth dose, even though there has been a recent small case series showing that 5/8 (63%) patients with negative to low positive titers showed boosting to high-positive titers after a fourth dose of the vaccine [11] . But patients who do not develop an antibody response can then be extra-cautious knowing that they are not well protected against future SRAS-COV-2 infection and morbidity/ mortality because of the infection [12, 13] . These patients can be considered for early monoclonal antibody treatment to reduce their chances of getting a serious infection as reported in this single institution case series [14] . It would also be prudent for the caregivers of these patients to be vaccinated to prevent infection. There are currently no guidelines for patients who continue to have undetectable antibody levels after the booster dose.

More studies are needed to assess the antibody and cellular responses of immunosuppressed transplant patients to vaccination in the peri-transplant period. These studies should sequentially monitor the antibody responses over time to look for attrition of antibody response, which is expected to be quicker in this population. 

mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2-preliminary report

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

Immunogenicity of a Single Dose of SARS-CoV-2

Messenger RNA Vaccine in Solid Organ Transplant Recipients

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

COVID-19 Mortality in Transplant Recipients

High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study

PhD1 Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience